Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 58

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 58
---
. Certain legal matters as to PRC law will be passed upon for us by Jingtian & Gongcheng. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable
prospectus supplement.

EXPERTS

The consolidated financial statements of Connect Biopharma Holdings Limited as of December 31, 2024 and 2023 and for the
years then ended, which are incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2024, have been so incorporated in reliance on the report of CBIZ
CPAs P.C., an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

44

The information in this prospectus is not complete and may be changed. We may not sell these securities until the Registration Statement filed with the Securities and Exchange Commission, of which this prospectus is a part, is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED SEPTEMBER 10, 2025

PROSPECTUS

Up to $150,000,000 of Ordinary Shares

Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited, a holding company incorporated in the Cayman Islands in November 2015
(“Connect,” the “Company,” the “Group,” “we,” “us,” “our,” “our company” and “Connect Biopharma”) is party to a sales agreement (the “Sales
Agreement”), with Cantor Fitzgerald & Co. (“Cantor”), dated April 15, 2022, as amended on June 10, 2025 and amended and restated on September 10, 2025, relating to the ordinary shares, par value $0.000174
per share (“Ordinary Shares”) offered by this prospectus. Under this prospectus, we may offer and sell Ordinary Shares having an aggregate offering price of up to $150.0 million from time to time through Cantor (the “Sales
Agent”), acting as our agent, in accordance with the Sales Agreement. As of September 10, 2025, we have not sold any Ordinary Shares under the Sales Agreement.

Sales of the Ordinary Shares, if any, under this prospectus may be